Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

Adding IMNN-001, a DNA-mediated immunotherapy, to standard-of-care treatment improved median overall survival by 14.7 months in patients with newly diagnosed advanced ovarian cancer, final clinical data from the OVATION 2 study shows.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

FDA approved relacorilant (Lifyorli), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA replication in cancer cells.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.

March 13, 2026

Vol.52 No.10

Clinical Roundup

Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows

A growing number of U.S. adults consider electronic cigarettes (e-cigarettes) more harmful than conventional cigarettes, UT Southwestern Medical Center researchers show in a study.

March 13, 2026

Vol.52 No.10

Clinical Roundup

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint

ROSELLA phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint.

February 27, 2026

Vol.52 No.08

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

YOU MAY BE INTERESTED IN

IMNN-001 improves median OS by over 14 months in newly diagnosed advanced ovarian cancer, phase II study shows

FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Researchers at VCU identify Achilles’ heel in lung cancer through common genetic mutation

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Growing number of U.S. adults wrongly think vaping is more harmful than smoking cigarettes, study shows

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint

Renew today!

Subscriber content

Never miss an issue!

Login